Study on Autoantibodies in Rheumatoid Arthritis Treatment
Author Information
Author(s): Teng YK Onno, Verburg Robert J, Verpoort Kirsten N, Diepenhorst Gwendolyn MP, Bajema Ingeborg M, van Tol Maarten JD, Jol-van der Zijde Els CM, Toes Rene EM, Huizinga Tom WJ, van Laar Jacob M
Primary Institution: Leiden University Medical Center
Hypothesis
The study investigates the relationship between autoantibody levels and clinical responses in refractory rheumatoid arthritis patients treated with immunoablative therapy.
Conclusion
The study found that lower avidity anti-cyclic citrullinated protein autoantibodies are associated with better clinical responses to immunoablative therapy in rheumatoid arthritis patients.
Supporting Evidence
- Three patients showed significant reductions in ACPA-IgG levels after therapy.
- Clinical responders had lower avidity ACPA-IgG and higher inflammation scores.
- Relapses were preceded by rising levels of low avidity ACPA-IgG.
Takeaway
Doctors looked at how certain antibodies in the blood of arthritis patients changed after treatment, and found that those with lower levels of a specific antibody did better.
Methodology
The study involved six patients with refractory rheumatoid arthritis who were treated with high-dose chemotherapy and autologous stem cell transplantation, with extensive monitoring of autoantibody levels and clinical responses.
Limitations
The study is limited by the small sample size and the variability in individual patient responses.
Participant Demographics
All patients had a median disease duration of 12 years and were seropositive for rheumatoid factor and anti-cyclic citrullinated protein antibodies.
Statistical Information
P-Value
0.05
Statistical Significance
p=0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website